Home » Stocks » SYRS

Syros Pharmaceuticals, Inc. (SYRS)

Stock Price: $13.16 USD -1.79 (-11.97%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
Market Cap 814.86M
Revenue (ttm) 9.90M
Net Income (ttm) -73.64M
Shares Out 45.78M
EPS (ttm) -1.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $13.16
Previous Close $14.95
Change ($) -1.79
Change (%) -11.97%
Day's Open 15.00
Day's Range 12.85 - 15.25
Day's Volume 3,657,017
52-Week Range 4.46 - 15.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to se...

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities a...

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7) The updated release reads: SYROS TO PRESENT AT 39TH ANNUAL J.P....

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive ...

Seeking Alpha - 3 weeks ago

Syros Pharmaceuticals doubled its stock price in 2020. Syros recently acquired SY-2101 from Orsenix.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has closed a prev...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new clinical data from it...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has acquired from...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive ...

Seeking Alpha - 2 months ago

Syros Pharmaceuticals' (SYRS) CEO Nancy Simonian on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the ...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new ...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live ...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacok...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present init...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive ...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of S.

Zacks Investment Research - 5 months ago

Syros (SYRS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Seeking Alpha - 5 months ago

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 5.00% and 45.57%, respectively, for the quarter ended June 2020.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the ...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial ...

Zacks Investment Research - 5 months ago

Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live ...

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for May 19th

Other stocks mentioned: AGFS, MIST, UNFI
Seeking Alpha - 8 months ago

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Syros Pharmaceuticals Inc (SYRS) delivered earnings and revenue surprises of 13.33% and 38.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for...

Benzinga - 8 months ago

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) were unchanged in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 8 months ago

Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 10 months ago

Syros, Beyond Oncology

Seeking Alpha - 10 months ago

Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 2.13% and -35.53%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 10 months ago

Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 11 months ago

Syros Pharmaceuticals Update: Still A Buy

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Syros Pharmaceuticals

The Motley Fool - 1 year ago

Investors appeared to like the addition of a well-known new board member.

InvestorPlace - 1 year ago

Syros Pharmaceuticals (SYRS) news for Wednesday about plans for developing new drugs and a $20 million payment have SYRS stock flying high.

Market Watch - 1 year ago

Global Blood Therapeutics Inc. and Syros Pharmaceuticals announced a partnership to develop and commercialize therapies for sickle cell disease and beta thalassemia.

Other stocks mentioned: GBT
24/7 Wall Street - 1 year ago

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.

Other stocks mentioned: ACAD, ALEC, AMRN, AVDL, BHC, BIIB, EPZM, GTHX, MGNX
Seeking Alpha - 1 year ago

Syros Pharmaceuticals' (SYRS) CEO Nancy Simonian on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 2.08% and 29.77%, respectively, for the quarter ended September 2019.

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CERS, NEPH, NOG, ZNGA
Zacks Investment Research - 1 year ago

Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 1 year ago

Syros Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

The Motley Fool - 1 year ago

Not every stock had a favorable reaction to earnings.

Other stocks mentioned: IBM, XOG
Seeking Alpha - 1 year ago

Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 14.04% and 7.58%, respectively, for the quarter ended March 2019.

Seeking Alpha - 1 year ago

Syros plunged 33% on Friday, April 5, after announcing a stock offering.

The Motley Fool - 1 year ago

The company announced the pricing of a stock offering. Despite the dilution, it's a well-timed move by management.

About SYRS

Syros Pharmaceuticals, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tum... [Read more...]

Industry
Biotechnology
IPO Date
Jun 30, 2016
CEO
Nancy Simonian
Employees
83
Stock Exchange
NASDAQ
Ticker Symbol
SYRS
Full Company Profile

Financial Performance

In 2019, SYRS's revenue was $1.98 million, a decrease of -3.32% compared to the previous year's $2.05 million. Losses were -$75.44 million, 21.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for SYRS stock is "Buy." The 12-month stock price forecast is 17.43, which is an increase of 32.45% from the latest price.

Price Target
$17.43
(32.45% upside)
Analyst Consensus: Buy